BRIEF published on 08/27/2026 at 19:04, 20 days 13 hours ago ABIONYX Pharma Updates on Mid-Year 2026 Financials Cash Position Financial Update Ophthalmology ABIONYX Pharma 2026 Revenue
PRESS RELEASE published on 08/27/2026 at 18:59, 20 days 13 hours ago Inside Information / Other news releases ABIONYX Pharma updates activity and cash position for H1 2026: revenue of €1.9M, cash balance of €26.9M before Research Tax Credits and grants. Company focuses on innovative therapies for sepsis Revenue Cash Position Innovative Therapies ABIONYX Pharma Activity Update
BRIEF published on 07/06/2026 at 20:05, 2 months 10 days ago ABIONYX: Details on Share Capital and Voting Rights Euronext Paris Share Capital Voting Rights AMF ABIONYX
BRIEF published on 07/06/2026 at 20:05, 2 months 10 days ago ABIONYX Monthly Voting Rights Update Euronext Paris Share Capital Voting Rights Financial Update ABIONYX Pharma
PRESS RELEASE published on 07/06/2026 at 20:00, 2 months 10 days ago Inside Information / Other news releases ABIONYX Pharma discloses monthly statement of total voting rights and shares. Company focuses on innovative medicines development with lipid science expertise Shares Total Voting Rights ABIONYX Pharma Innovative Medicines Lipid Science
BRIEF published on 07/06/2026 at 19:19, 2 months 10 days ago ABIONYX's Half-Yearly Review of the Liquidity Contract Liquidity Transactions TP ICAP Actions ABIONYX Pharma
BRIEF published on 06/30/2026 at 19:13, 2 months 16 days ago ABIONYX Pharma Secures Funding to Advance Sepsis Treatment ABIONYX Pharma CER-001 Financial Funding Sepsis Treatment ApoA-I Platform
BRIEF published on 06/30/2026 at 19:13, 2 months 16 days ago ABIONYX Pharma is expanding rapidly following its General Meeting ABIONYX Pharma Sepsis CER-001 General Assembly 2026 ApoA-I Platform
PRESS RELEASE published on 06/30/2026 at 19:08, 2 months 16 days ago Inside Information / Other news releases ABIONYX Pharma scales up operations after securing resources, focusing on value creation in inflammation and sepsis treatment. Updates on pivotal clinical trial, financial visibility, and scientific platform development Financial Resources Clinical Trial ABIONYX Pharma Sepsis Inflammation Treatment
BRIEF published on 06/18/2026 at 07:35, 2 months 29 days ago ABIONYX Pharma Completes Successful EUR 33 Million Financing Capital Increase Bond Financing ABIONYX Pharma Fenja Capital Sepsis Research
Published on 09/16/2026 at 23:45, 9 hours 5 minutes ago Galway Metals Settles Claim by Former Employee with Cash and Share Payments
Published on 09/16/2026 at 21:30, 11 hours 20 minutes ago Torq Completes $1.7 Million Private Placement
Published on 09/16/2026 at 16:55, 15 hours 55 minutes ago CORRECTION FROM SOURCE: SLAM Reports 1.60% Copper Equivalent Over 14.45 Meters in Hole GW26-33; Trenching Gold-Antimony Targets on Moose Lake Project
Published on 09/16/2026 at 15:00, 17 hours 50 minutes ago 2026 Canada's Top 40 Under 40(R) Honourees Announced
Published on 09/16/2026 at 14:00, 18 hours 50 minutes ago Ameriwest Awaits Bornite Core Assay Results and Provides Q3 2026 Corporate Update
Published on 09/17/2026 at 08:35, 15 minutes ago OCI N.V. statement regarding an open letter from shareholders
Published on 09/17/2026 at 08:05, 45 minutes ago CookieYes Launches MCP Server to Manage Cookie Consent Inside Claude and ChatGPT
Published on 09/17/2026 at 07:15, 1 hour 35 minutes ago Infracore ergänzt ihr Angebot für die Immobilien des Spitals Wetzikon und verlängert dessen Gültigkeit bis zum 31. Oktober 2026
Published on 09/16/2026 at 17:45, 15 hours 5 minutes ago Report on share repurchases from 9 to 15 September 2026
Published on 09/16/2026 at 07:00, 1 day 1 hour ago bioMérieux Receives IVDR Class D CE Marking for BIOFIRE® Respiratory 2.1 plus Panel and BIOFIRE® FILMARRAY® Pneumonia plus Panel, the first syndromic tests including MERS-CoV to achieve this certification
Published on 09/15/2026 at 18:00, 1 day 14 hours ago Report on the Combined General Meeting of the 10th of September 2026
